Bausch Health Companies BHC Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net

Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net at other companies

PBH

Prestige Consumer HealthcarePBH

——

Bausch + LombBLCO

——

OrganonOGN

——

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$2.5B+11.7%

Operating income-$950.0M-444%

Net income-$1.4B-2,353%

EPS (diluted)-$3.82-2,287%

Balance sheet

See full

Cash & equivalents$1.3B+13.4%

Total debt$20.8B-3.5%

Total equity-$2.1B-74.0%

Total assets$24.5B-7.3%

Cash flow

See full

Operating cash flow$230.0M+9.0%

CapEx$109.0M-5.2%

Free cash flow$121.0M+26.0%

Valuation

See full

Market cap$1.79B-15.9%

Enterprise value$21.24B-5.6%

P/S0.2×0.0×

Profitability

See full

Gross margin71.4%—

Operating margin5.6%-10.3pp

Net margin-1.9%-0.9pp

FCF margin9.8%-2.8pp

Returns & leverage

See full

Return on equity-70.1%—

Debt / equity45.2×—

Current ratio1.3×0.0×

Where this comes from

Reported directly by Bausch Health Companies in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet.

The official record: Bausch Health Companies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch Health Companies's debt instrument, unamortized discount (premium) and debt issuance costs, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bausch Health Companies's debt instrument, unamortized discount (premium) and debt issuance costs, net?: Bausch Health Companies (BHC) reported debt instrument, unamortized discount (premium) and debt issuance costs, net of -$552M in Q1 2026.